Evans Blue Analgesic Targets VNUT for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain are limited in efficacy and often come with side effects, necessitating the development of novel therapeutic agents that can effectively target and reduce chronic pain without adverse reactions.
Innovation Solution
A pharmaceutical and food composition incorporating Evans blue as an active ingredient, which targets all neurons and microglia cells in the spinal cord, specifically inhibiting the vesicular nucleotide transporter (VNUT) of dorsal root ganglia cells to suppress hyperexcitation and relieve pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional substances that reduce neurotic excitability or sensory axon conduction are administered against neuropathic pain, then pain relief is achieved, but side effects occur and efficacy is limited
Solution Approach 1:
Evans blue acts as an intermediary substance that binds to albumin and selectively targets hyperexcited sensory neurons through the blood-brain barrier. It mediates pain relief by suppressing neuronal hyperexcitability without the harmful side effects of traditional analgesics, thereby resolving the contradiction between efficacy and safety
Solution Approach 2:
The invention changes the chemical parameter by using Evans blue, a stable azo dye with unique properties (binds to albumin, crosses blood-brain barrier, suppresses neuronal excitation). This parameter change enables effective pain treatment without the side effects associated with traditional pain medications
2Reliability
If current pain medications are used to treat chronic neuropathic pain, then some pain relief is provided, but the treatments are limited in efficacy and cannot effectively target hyperexcitation of sensory neurons
Solution Approach 1:
Evans blue serves as a specialized intermediary that specifically targets the pathophysiological mechanism of neuropathic pain (hyperexcitability of sensory neurons). It crosses the blood-brain barrier and selectively suppresses neuronal hyperexcitation, providing adaptable and effective treatment for neuropathic pain mechanisms that traditional medications cannot address
Solution Approach 2:
The invention applies a parameter change by introducing Evans blue, which has unique chemical properties (azo dye structure, albumin binding capability, neuronal suppression effect) that make it specifically adaptable to treating neuropathic pain mechanisms, thereby improving both efficacy and applicability
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition or food composition including Evans blue for prevention or treatment of chronic pain diseases. The administration of Evans blue according to the present disclosure can effectively reduce chronic pain, such as neuropathic pain. In particular, Evans blue targets mainly VNUT protein of dorsal root ganglia, which plays an important role in the secretion of ATP from the distal end of the afferent nerve and can relieve the pain using drugs continuously without side effects so that it can be efficiently used as an analgesic for various kinds of pain caused by chronic pain diseases.